These effects of IFNγ are likely to be transduced via the JAK/STAT pathway [14, 20], which is implicated in resistance to contemporary targeted drugs used for the treatment of patients with CLL [16]. The gene discussed is IFNG; the disease is B-cell chronic lymphocytic leukemia.